Serial 88829932
Live / Registered — Registered (as of 06 Dec 2022)
What this means for you
Registered since 06 Dec 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88829932
- Registration number
- 6918743
- Mark type
- Design / logo
- Filed
- 11 Mar 2020
- Published for opposition
- 21 Jul 2020
- Registered
- 06 Dec 2022
- Attorney of record
- Paul C. Llewellyn
Goods and services
- Class 005 — Pharmaceuticals: pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
Owner
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
- Sarepta Therapeutics, Inc., Cambridge, MA, US
Prior registrations
Prosecution history
- 06 Dec 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Dec 2022 — REGISTERED-PRINCIPAL REGISTER
- 03 Nov 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 02 Nov 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 01 Nov 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 14 Oct 2022 — USE AMENDMENT FILED
- 31 Oct 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 14 Oct 2022 — TEAS STATEMENT OF USE RECEIVED
- 09 Sept 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Sept 2022 — SOU EXTENSION 4 GRANTED
- 07 Sept 2022 — SOU EXTENSION 4 FILED
- 07 Sept 2022 — SOU TEAS EXTENSION RECEIVED
- 05 Mar 2022 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Mar 2022 — SOU EXTENSION 3 GRANTED
- 03 Mar 2022 — SOU EXTENSION 3 FILED